Iovance Biotherapeutics, Inc. (IOVA) Total Assets by Year
Iovance Biotherapeutics, Inc. closed fiscal year 2025 with $913.2M in total assets, $214.6M in total liabilities and $698.6M in shareholder equity. This represents an increase of 0.3% from the prior fiscal year. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Iovance Biotherapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
IOVA Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY22DEF 14A | FY21DEF 14A | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $913.2M+0.3% | $910.4M+16.7% | $780.4M+17.5% | $664.0M-14.6% | $777.3M+1.2% | $768.5M+123.0% | $344.7M-28.3% | $480.8M+209.5% | $155.4M-9.6% | $171.9M+62.7% | $105.7M+127.2% | $46.5M+134.0% | $19.9M+67467.6% | $29K-94.8% | $568K |
| Total Liabilities | $214.6M+7.3% | $200.0M+2.2% | $195.7M+19.1% | $164.3M+5.6% | $155.7M+39.0% | $112.0M+145.1% | $45.7M+212.3% | $14.6M+47.9% | $9.9M+99.1% | $5.0M+204.8% | $1.6M-1.9% | $1.7M-26.8% | $2.3M-80.0% | $11.3M-15.0% | $13.3M |
| Total Equity | $698.6M-1.7% | $710.4M+21.5% | $584.6M+17.0% | $499.6M-19.6% | $621.7M-5.3% | $656.5M+119.6% | $299.0M-35.9% | $466.2M+220.4% | $145.5M-12.8% | $166.9M+60.5% | $104.0M+132.0% | $44.8M+154.8% | $17.6M+255.5% | -$11.3M+11.4% | -$12.8M |
IOVA Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $915.5M+0.9% | $925.7M-4.2% | $913.2M+0.3% | $904.9M-8.7% | $907.4M-5.9% | $966.7M+11.1% | $910.4M+16.7% | $991.1M+16.3% | $964.3M+27.3% | $869.8M+5.5% | $780.4M+17.5% | $852.3M+56.1% |
| Total Liabilities | $179.5M-14.1% | $203.9M+2.5% | $214.6M+7.3% | $202.7M-6.9% | $208.9M+6.7% | $198.9M+4.8% | $200.0M+2.2% | $217.7M+22.1% | $195.8M+9.5% | $189.8M+20.2% | $195.7M+19.1% | $178.3M+17.2% |
| Total Equity | $736.0M+5.4% | $721.8M-6.0% | $698.6M-1.7% | $702.3M-9.2% | $698.5M-9.1% | $767.9M+12.9% | $710.4M+21.5% | $773.5M+14.8% | $768.5M+32.8% | $680.0M+2.0% | $584.6M+17.0% | $674.0M+71.2% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Iovance Biotherapeutics, Inc. financials
Frequently Asked Questions
What was Iovance Biotherapeutics, Inc.'s total assets in fiscal year 2025?
Iovance Biotherapeutics, Inc. closed fiscal year 2025 with $913.2M in total assets, $214.6M in total liabilities and $698.6M in shareholder equity.
How fast is Iovance Biotherapeutics, Inc.'s total assets growing?
Iovance Biotherapeutics, Inc. (IOVA) total assets rose by 0.3% year over year, from $910.4M to $913.2M in fiscal year 2025.
How has Iovance Biotherapeutics, Inc.'s total assets changed over the years?
Across the 15 fiscal years this page covers, Iovance Biotherapeutics, Inc. (IOVA) total assets went from $568K in fiscal year 2011 to $913.2M in fiscal year 2025.
What was Iovance Biotherapeutics, Inc.'s total assets in the most recent quarter?
Iovance Biotherapeutics, Inc. (IOVA) reported $915.5M in total assets in Q2 2026. This represents an increase of 0.9% from the same quarter a year earlier.
What does total assets mean on a financial statement?
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Iovance Biotherapeutics, Inc. (IOVA) reported on that line in every period on record.